| scholarly article | Q13442814 |
| P2093 | author name string | Peng Gao | |
| Xu Chen | |||
| Ya-Wen Wang | |||
| Ran-Ran Ma | |||
| Wen-Jie Zhu | |||
| Hai-Ting Liu | |||
| P2860 | cites work | Insights into Chemoresistance of Prostate Cancer | Q26795589 |
| Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma | Q26800007 | ||
| Use of miRNAs as biomarkers in sepsis | Q26801909 | ||
| Escalating and de-escalating treatment in HER2-positive early breast cancer | Q28069895 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q33862786 | ||
| Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer | Q34587948 | ||
| A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer | Q35237480 | ||
| HER2-directed therapy: current treatment options for HER2-positive breast cancer | Q35551522 | ||
| The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. | Q35793641 | ||
| PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim. | Q35834635 | ||
| AKT signaling in ERBB2-amplified breast cancer | Q36563578 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1. | Q36771905 | ||
| Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. | Q37364111 | ||
| HER2-positive gastric cancer | Q37468290 | ||
| α-Tocopheryl succinate induces apoptosis in erbB2-expressing breast cancer cell via NF-κB pathway | Q37729171 | ||
| miRNAs in PAH: biomarker, therapeutic target or both? | Q38216486 | ||
| The potential of miRNAs as biomarkers for multiple myeloma | Q38237446 | ||
| Mitochondrial dysfunction in cancer chemoresistance | Q38238332 | ||
| Targeting HER2 in ovarian and uterine cancers: challenges and future directions | Q38249126 | ||
| miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies | Q38253957 | ||
| Targeting HER2 in the treatment of non-small cell lung cancer | Q38324334 | ||
| miRNA expression patterns in chemoresistant breast cancer tissues | Q38469755 | ||
| The Role of MicroRNAs in the Chemoresistance of Breast Cancer | Q38574546 | ||
| miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism | Q38680966 | ||
| ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts | Q38936712 | ||
| Tumor microenvironment-mediated chemoresistance in breast cancer. | Q38964565 | ||
| Activated ERBB2/HER2 licenses sensitivity to apoptosis upon endoplasmic reticulum stress through a PERK-dependent pathway | Q39031591 | ||
| Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody. | Q39315742 | ||
| HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer | Q39385623 | ||
| In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models | Q39630334 | ||
| Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer | Q39772391 | ||
| Die-hard survivors: heterogeneity in apoptotic thresholds may underlie chemoresistance | Q41392733 | ||
| A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival | Q44682357 | ||
| miRNA and cancer; computational and experimental approaches | Q45868256 | ||
| The role of miRNAs in drug resistance and prognosis of breast cancer formalin-fixed paraffin-embedded tissues. | Q52972833 | ||
| Effects of HER2 genetic polymorphisms on its protein expression in breast cancer. | Q53361777 | ||
| The PI3K/AKT/mTOR interactive pathway. | Q54274892 | ||
| Aneuploidy identifies subsets of patients with poor clinical outcome in grade 1 and grade 2 breast cancer | Q87205305 | ||
| P433 | issue | 52 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 89631-89642 | |
| P577 | publication date | 2017-08-09 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway | |
| P478 | volume | 8 |
| Q90471944 | A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy |
| Q47728851 | Baicalin modulates NF-κB and NLRP3 inflammasome signaling in porcine aortic vascular endothelial cells Infected by Haemophilus parasuis Causing Glässer's disease |
| Q55234349 | Transcriptional Profiling of Host Cell Responses to Virulent Haemophilus parasuis: New Insights into Pathogenesis. |
Search more.